Philippe Maitre To Head Onxeo US
This article was originally published in Scrip
Executive Summary
Oncology focused Onxeo SA. has appointed Philippe Maitre head of its new US subsidiary as executive vice president and chief of US operations. Maitre brings over 35 years' experience to the company and previously served as CEO and co-founder of the biotech mAbRx. Prior to this, he was CEO at the cancer vaccine company Anosys. Onxeo's new US subsidiary is headquartered in New York.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.